Dr. Ronald Roth D.Acu · Cellular Nutrition · Published October 12, 2001 · Edit log

Iron and Manganese

Iron (Fe) and Manganese (Mn) are associated trace elements considered essential to human health. As with many other associated mineral pairs, the two compete for the same intestinal transporter, so their status is closely linked. Many forms of iron cause constipation or gastric upsets when supplemented, which is one reason manganese status is worth checking alongside iron - though, as covered below, manganese cannot correct an iron deficiency itself.

Iron and manganese are absorbed through the same intestinal transporter, DMT1 (divalent metal transporter 1), and they compete for it._[3] This interaction is not a theoretical consideration - it is the main factor governing how much of either element is taken up. Because DMT1 is upregulated when iron stores are low, iron deficiency increases manganese absorption rather than reducing it,_[4] and blood manganese tends to run inversely to iron status - children with iron deficiency anaemia have been found to carry raised whole-blood manganese._[8] Iron also matters on the other side of manganese's toxicity: in cell studies, restoring intracellular iron protects against manganese's toxic effects, while iron depletion makes them worse._[5]

Manganese cannot correct an iron deficiency. Iron deficiency is a depletion of iron stores, and only iron - from diet, oral supplementation, or infusion - can restore them. Because the two elements compete at DMT1, taking manganese while iron is low may reduce absorption of what dietary iron is available.

Editorial recommendation - manganese supplementation

The reference figures for manganese - the US Tolerable Upper Intake Level of 11 mg per day_[12] and the EFSA safe level of intake of 8 mg per day_[13] - describe total daily intake, most of which comes from grains, nuts, legumes and tea. Manganese in those foods is poorly absorbed. Removing phytic acid from a soy formula raised absorption 2.3-fold, from 0.7% to 1.6%,_[6] and adding calcium to a feed reduces manganese absorption as well._[7]

A soluble supplement salt such as manganese gluconate bypasses that inhibition entirely. Those reference figures therefore cannot be read as permission to take the same amount in supplement form - a few milligrams of a soluble salt is not equivalent to a few milligrams spread through a day's food. For scale at the other end, the highest oral doses in any published human trial were manganese ascorbate at 228 - 304 mg per day in glucosamine and chondroitin osteoarthritis studies,_[14]_[15] approximately 30 - 40 mg of elemental manganese, or three to four times the Upper Intake Level.

For people whose diet is low in manganese, the cautionary position of this site is 1 mg manganese gluconate, about 10 doses per month - roughly one dose every three days.

These are editorial recommendations based on observed tolerance. They are not values derived from a clinical trial, and they are deliberately set well below the official total-intake figures for the absorption reasons given above.

A note on the products sold today

Manganese supplements are commonly sold at 10 mg per capsule, and some at 50 mg. Measured against the figures above, a 10 mg capsule delivers the whole Tolerable Upper Intake Level in one soluble dose,_[12] and 50 mg exceeds the highest amount administered in any published human trial._[14]_[15] This is not hypothetical: the glucosamine and chondroitin products described above delivered roughly 30 - 40 mg of elemental manganese daily to people who were buying them for their joints, not for their manganese.

The position of this site is that doses at that level are experimental at best, and difficult to defend as nutrition. In our own observation they bring on overload symptoms readily, in some cases from a single dose - an observation rather than a trial finding, and offered here as a reason for caution, not as evidence.

How people test this in practice

Because no blood test for manganese status exists, a clinician cannot measure it, and people who suspect a shortfall in a manganese-poor diet generally settle the question empirically instead.

The usual approach is a single dose of 2 mg manganese gluconate. Manganese and iron fall into the fast-acting group when someone is low: a single dose commonly produces a noticeable biological effect, felt to some degree by most people, and it typically appears within 1 to 24 hours.

How the outcome is generally read:

A clear improvement is treated as a useful sign, though not as proof - feeling something after taking a supplement is common, whatever the cause.
No change is not taken to rule a shortfall out, since one dose does not refill a depleted store.
A worsening is a reason to stop.

Whatever the outcome, symptoms that cause concern are a matter for a doctor rather than for a supplement.

Routine blood work does not include manganese at all, and assesses iron alone. Of the iron measures, ferritin is the most useful and is the recommended first-line test, since it correlates with iron stores._[21]_[22] Its limitation is that ferritin is an acute-phase reactant, rising with inflammation, infection, malignancy and liver disease, so a normal or raised value does not exclude iron deficiency._[23]_[24] Where inflammation confounds the picture, ferritin is interpreted alongside transferrin saturation and soluble transferrin receptor._[23] Read on its own, it can produce both false reassurance and unnecessary supplementation, which is a particular concern with polycythemia or thalassemia.

Pregnant women are the most vulnerable targets for either insufficient, or excessive iron supplementation, with the latter being able to trigger 'Toxemia of Pregnancy' (high iron causes excessive sodium retention), and in which case higher amounts of Folic acid should have been supplemented instead, which lowers sodium

Likewise, blood loss, or malabsorption are considered to be the main causes for low iron after ruling out any of a number of blood disorders, and other factors such as excessive calcium, zinc, or magnesium levels can reduce iron values as well. What is less often considered is the reverse of the usual reasoning: where iron is found to be low, manganese may well be low also. The two elements share the same absorption pathway, and the circumstances that deplete one - a restricted or one-sided diet, malabsorption, or long-standing poor intake - are frequently the very same circumstances that deplete the other. A finding of iron deficiency is a reason to consider manganese, not a reason to assume it has been excluded.

This is complicated by an asymmetry in testing. A physician investigating fatigue will order iron studies as a matter of routine, but there is no equivalent for manganese. Whole blood manganese varies widely between individuals and correlates poorly with outcomes,_[9] and reviews of the field state plainly that no qualified biomarker of manganese status has been established._[10] The measures that come closest - serum manganese combined with lymphocyte manganese-dependent superoxide dismutase activity, and possibly blood arginase - are research tools rather than anything a patient will be offered at a clinic._[11] The practical result is a blind spot: iron is measured, manganese is not.

Editor's note: the established position that manganese deficiency is uncommon in humans should be read against that blind spot. The claim is widely asserted, but it does not rest on population testing, because routine testing does not exist - and where testing is done, its accuracy as a measure of status is questionable. An absence of diagnoses is not evidence of an absence of cases. Until a validated status marker is in general clinical use, the defensible position is that the prevalence of manganese deficiency is unknown, rather than low.

It should be stressed that the relationship between the two elements is not a simple inverse. Competition at DMT1 governs how much of each is absorbed, while dietary supply governs how much of each is available to be absorbed in the first place, and those two forces do not always pull in the same direction. All four combinations occur:

Low Fe - Low Mn	A shared dietary cause. A restricted or one-sided diet, or malabsorption, depletes both. Upregulated uptake cannot compensate when there is little of either to absorb.
Low Fe - High Mn	Iron deficiency upregulates DMT1, raising manganese uptake from whatever supply exists. Raised whole-blood manganese has been documented in children with iron deficiency anaemia._[8]
High Fe - Low Mn	The same competition for the shared transporter can run in reverse: sustained high iron intake would be expected to limit manganese uptake,_[3] the situation to watch for in anyone supplementing iron long term.
High Fe - High Mn	Adequate or excess supply of both, from diet, supplementation, or environmental exposure.

Which of the four applies in a given person depends on diet, absorption, supplementation and exposure together - which is another reason a single blood value, of either element, is a weak basis for a decision.

Cellular levels of iron best correspond to actual symptoms of excess or deficiency, in contrast to blood levels, which unfortunately fluctuate considerably under various medical situations, particularly with infections. Following are some interactions of iron and manganese with other elements:

There is also a synergistic and antagonistic interaction between Iron + Manganese and B-Vitamins, whereby these interactions will change under various medical situations as well. For instances, with kidney disease, a fine balance needs to be maintained between folate and iron levels since one will otherwise inhibit the other. The same applies with adrenal disturbances, except they will affect the balance between iron and Vitamin B1.

Stomach acid levels heavily interact synergistically with iron and manganese, whereby the absorption of both elements is enhanced by higher HCl acid levels, while an increase in iron or manganese will generally, but not always, result in raised stomach acid levels. Since Calcium and Magnesium have the exact opposite effect on stomach acid levels, their interaction with iron and manganese have a major impact on medical situations that are associated with raised or lowered stomach acid levels (for details see "Calcium & Magnesium").

Liver Functions:

Excessive manganese and/or iron storage can set the stage for tumor development as much as 10 or 20 years before a benign or malignant growth develops - subsequent to the exposure or intake of substances that have an adverse effect on Liver Chemistry, which includes:

Alcohol
Green Tea extract
Antifungal medications
Acetaminophen (Tylenol)
Viral infections (e.g. hepatitis)
Cholesterol-lowering (statin) drugs
Food-related mold / mycotoxins (aflatoxin)
Proton pump inhibitors (Nexium, Prilosec, Prevacid...)
Hormones (e.g. estrogen, androgen, anabolic steroids)
Heavy metal / toxic exposure (PVC, arsenic, pesticides)
Dry cleaning chemicals (tetrachloroethylene / perchloroethylene)
Genetic disposition (alpha-1 antitrypsin deficiency, hemochromatosis)
Foods / beverages heated in plasticware containing Bisphenol A (BPA)
Herbal / nutritional supplements (Lakota, kava, devil's claw, celandine, comfrey, chaparral)
Evening primrose oil (EPO) and Conjugated Linoleic Acid (CLA) impair liver functions in some individuals. Symptoms include mild, but chronic nausea

Many other factors or medications (certain antibiotics, anesthetics, tricyclic antidepressants, anti-hypertensive, antiviral, anti-seizure... drugs) can result in higher manganese (and some in excessive iron) storage, regardless of actual manganese or iron consumption. In addition, certain foods or beverages (grapefruit or grapefruit juice) can alter the liver's ability to metabolize many toxins and drugs, resulting in higher iron and/or manganese retention as well.
By the time a tumor develops, patients don't always exhibit liver storage of these elements any longer, or they may have dropped below normal as a result of perimenopausal or postmenopausal hormone changes, along with reduced stomach acid levels.
From many years of following patients with a similar medical history, it appears that if stomach acid levels and liver functions are normalized in time, patients remain largely tumor-free. That approach is also helpful after cancer has developed, where following successful therapy, cancer is more likely to stay in remission. High manganese levels are linked to estrogen receptor-positive, while low manganese levels are linked to estrogen receptor-negative cancers.

The primary function of Iron in the body is the formation of hemoglobin, the essential oxygen-carrying component of the red blood cell (RBC). In combination with protein, iron is carried in the blood to the bone marrow, where with the help of copper, it forms hemoglobin. Red blood cells pick up oxygen from the lungs and distribute it to the rest of the tissues, all of which need oxygen to survive. Iron absorbed into the blood is usually bound to the protein transferrin and goes mainly to the bone marrow, where it can be used to make red blood cells.
Myoglobin is a red, iron-containing protein, which stores oxygen for muscle contraction. There are about 3 mg to 5 gm of iron in the body, of which hemoglobin represents 65%, while about 30% occurs as ferritin, which is the iron storage complex found in the liver, spleen and bone marrow. Neutrophils (white blood cells) depend on iron to help generate superoxide to function as a bacteria-destroying agent, whereby inadequate iron levels reduce the effectiveness of the immune system. With severe iron deficiency, hemoglobin levels decline and the packed volume of red blood cells, the hematocrit, declines.

Heme Iron from meat is considerably more absorbable_[1] than iron from all plant / vegetable sources. Many vegans have trouble obtaining sufficient iron from the diet alone since phytates present in whole grains and oxalates found in certain vegetables may bind to some of the iron and reduce absorption.

Iron deficiency is more common during infancy, childhood, adolescence, pregnancy, menstruation, chronic infections, low stomach acid (sometimes from low salt intake), chronic diarrhea, impaired absorption (celiac disease), or bleeding.

The elderly may become iron deficient due to inadequate dietary intake or poorer absorption of iron. Vitamin C, protein, niacinamide and sufficient stomach acid all help iron absorption.

Iron Toxicity (high organ storage of iron) and/or high blood levels of iron are associated with an increased risk of free radical damage and cancer. Ferritin levels are a good indication of iron storage levels. Normal values for females range from 18 - 180 ng/ml (mcg/L), and 18 - 270 ng/ml for males. Levels below 15 ng/ml suggest very depleted iron reserves, and higher ferritin (> 350 ng/ml) can be a risk factor for cardiovascular disease and diabetes. Free radicals formed as a result of high iron can attack low-density lipoproteins (LDL) and subsequently lead to fatty plaque buildup, damage to the walls of arteries, as well as heart muscle tissue.

Iron supplements frequently cause constipation or stomach complaints, which may result from the use of ferrous sulfate, or similar hard-to-digest forms of iron. Other types of iron such as ferrous gluconate, ferrous fumarate, or ideally Chelated Iron Supplements are generally better tolerated, and there are also water-soluble iron products that are probably the least problematic on the body, and cause less of these effects.

Manganese is a cofactor in glucose metabolism, and manganese supplementation improved glucose tolerance in mice on a high-fat diet._[16] In humans the relationship isn't one-directional: plasma manganese shows a U-shaped association with type 2 diabetes, with risk raised at both low and high levels,_[17] so more manganese is not simply better for blood sugar. Cholesterol-lowering drugs frequently raise manganese levels.
Manganese is not estrogenic. It acts on the hypothalamus to stimulate luteinizing hormone secretion,_[18] an effect studied in animals as an endocrine-disruption hazard - manganese-induced precocious puberty._[19] Higher blood manganese is associated with lower bone mineral density, most pronounced in postmenopausal women,_[20] the opposite of what would help with osteoporosis. No human evidence supports manipulating manganese levels to delay or hasten menopause, or to restart a menstrual cycle.

Manganese is a cofactor in numerous enzyme systems, including manganese superoxide dismutase, arginase, and enzymes of bone matrix formation._[10] None of asthma, carpal tunnel syndrome, deafness, epilepsy, infertility, low libido, or recurrent joint dislocation has controlled human trial evidence behind manganese supplementation as a treatment - an enzyme that requires a cofactor is saturated at ordinary intake, and being a cofactor does not establish that more of it treats a condition in someone who isn't deficient. On the other hand, high manganese levels increase the risk for tendon / ligament tears.

Manganese is important to many enzyme systems such as protein metabolism, bone formation, and the synthesis of L-dopamine and cholesterol, as well as carbohydrate metabolism, where it is required for the synthesis of glucose from non-carbohydrate substances (gluconeogenesis). As a co-factor in glycolysis, manganese aids glucose metabolism.
It is also needed for normal brain function,_[2] blood clotting, and DNA and RNA synthesis, and it activates the enzyme responsible for the formation of urea. Manganese may help with some symptoms of Parkinson's disease such as muscle rigidity and twitching, although an excessive level of manganese can in itself produce Parkinsonian syndrome from a loss of dopamine in the brain cells. L-dopa, which converts to dopamine in the brain, is used in the treatment of manganese toxicity to reduce the symptoms.
High levels of manganese can produce violence and other mental changes, including a psychiatric disorder resembling schizophrenia.

When people supplement certain herbs to "cleanse" their liver, they will always affect manganese and iron status. For instance, by taking Devil's Claw on an ongoing basis, they will eventually raise manganese and iron levels. On the other hand, taking higher amounts of Milk Thistle will in time decrease manganese and iron stores, which can be an advantage with hemochromatosis (excess iron storage disease), where regular consumption of milk thistle, RNA / DNA, zinc, magnesium and Vitamin B2 - as individually matched - will return iron levels closer to normal, and frequently eliminate the need for phlebotomies.

Iron

Manganese

Iron

AGE

0-6 months
6-12 months
1-10 years

11-18 years male
19+ years male

11-18 years fem.
19-50 years fem.
50+ years fem.

pregnant
lactating

-------------------
UL
Therapeutic Range

DRI (RDA)

0.27mg AI
11mg
7mg - 10mg

8mg - 11mg
8mg

8mg - 15mg
18mg
8mg

27mg
9mg - 10mg


40mg - 45mg
10mg - 900mg +

Manganese

AGE

0-6 months
6-12 months
1-10 years

11-18 years male
19+ years male

11-18 years fem.
19-50 years fem.
50+ years fem.

pregnant
lactating

-------------------
UL
Therapeutic Range

DRI (RDA)

0.003mg AI
0.6mg AI
1.2 - 1.9mg AI

1.9 - 2.2mg AI
2.3mg AI

1.6mg AI
1.8mg AI
1.8mg AI

2.0mg AI
2.6mg AI


2mg - 11mg
10mg - 200mg +

The Tolerable Upper Intake Level for manganese is 11 mg/day (US Institute of Medicine); EFSA has since set a safe intake of 8 mg/day. Both describe total daily intake, most of it from high-phytate foods absorbed at roughly 1 - 2%. A soluble supplement salt bypasses that inhibition, so these figures are not a licence to take the same amount as a supplement - see the editorial recommendation in the article above.

The Therapeutic Range shown is a record of doses reported in the literature, not a recommended intake. The highest published human trial doses came from glucosamine / chondroitin osteoarthritis products containing manganese ascorbate at 228 - 304 mg/day, roughly 30 - 40 mg elemental manganese.

Best time to take Iron: Morning - afternoon, with sufficient food to prevent stomach irritation.

Best time to take Manganese: Morning - evening, with sufficient food to prevent stomach upsets, but avoid taking manganese antagonists at the sametime, listed below.

Cellular / Intracellular Attributes and Interactions:

Iron Synergists: Phosphorus, bismuth, germanium, nickel, manganese, copper, Vitamin A, Vitamin B1, Vitamin C, Vitamin D, folate, niacin, niacinamide, lecithin, protein.

Manganese Synergists: Sodium, lithium, silicon / silica, cobalt, chromium, PABA, biotin, niacin / niacinamide, Vitamin E, choline, sugar*.

Iron Antagonists / Inhibitors: Zinc, calcium, magnesium, tin, cobalt, gallium, IP6, Vitamin B2, B5, B12, Vit E, folate*, caffeine, curcumin, oxalic acid, insoluble fiber, rice (phytates), tea (tannic acid), soy protein, dairy (casein), oil of oregano.

Manganese Antagonists / Inhibitors: Potassium, magnesium, calcium, iodine, nickel, boron, Vitamin B1, Vitamin B6, Vitamin B15, Vitamin C, iron*, sugar*.

* These can have synergistic or antagonistic action, depending on hypoglycemic or hyperglycemic tendencies.

High/Low Levels / Deficiency / Toxicity - Symptoms and Risk Factors:

Low Iron: Fatigue, anemia, depression, dizziness, asthma, gastrointestinal disorders, pale skin, miscarriage, amenorrhea(failure to menstruate), dysmenorrhea(painful periods), migraine-headaches, Ménière'sdisease, learning difficulties, weak immune system, restless leg / legs syndrome, ovarian cysts (left), delayed development in infants and children.

Low Manganese: No reproducible manganese deficiency syndrome has been established in free-living humans, and no qualified biomarker of manganese status exists_[10] - so its prevalence is unknown rather than known to be low.

Symptoms historically attributed to low manganese - including PMS, infrequent menstrual cycles, ovarian cysts, joint dislocations, asthma and migraine - are not supported by controlled human evidence. See the evidence review below.

High Iron: Hemochromatosis, migraine-headaches, arthritis, high blood pressure, heart disease, liver disease, dizziness, gastrointestinal disorders, nausea, higher risk for several cancers, fibroid tumors, benign prostatic hypertrophy (BPH), edema, constipation (high supplementation), diabetes, preeclampsia, lowered IQ in children.

High Manganese: Chronic excess causes manganism, a parkinsonian syndrome with tremor, rigidity, gait and balance disturbance, and cognitive or psychiatric change._[25]_[26] Risk is greatest with inhalation exposure, with impaired biliary clearance in liver disease, and with parenteral nutrition.

Higher blood manganese is associated with lower bone mineral density, most pronounced in postmenopausal women._[20] Plasma manganese shows a U-shaped association with type 2 diabetes, with risk raised at both low and high levels._[17]

Iron Sources: Meat, fish, shellfish, nuts, seeds, eggs, molasses, wheat germ, whole-grain products, raisins, beans.

Manganese Sources: Nuts, seeds, whole-grain products, wheat germ, seaweed, beans, peas, ginger, coffee.

Table key

DRI: Dietary Reference Intake
RDA: Recommended Dietary Allowance
AI: Adequate Intake
UL: Tolerable Upper Intake Level

Therapeutic Range

Doses reported in clinical or therapeutic use in the published literature. These are a record of doses that have been administered, in many cases as medication rather than as a nutrient, and they may exceed the UL. They are not intakes recommended by this site.

Evidence Review

Critical Scientific Evaluation of Iron and Manganese Interactions, Status Testing and Supplementation

A Comparative Review of Historical Alternative Claims and Contemporary Biomedical Evidence

AI-assisted literature review · 21 peer-reviewed sources · 22 August 2026

What follows is a separate document that examines the claims in the article above against the current biomedical literature, reproduced here in full.

The Iron–Manganese Transport Relationship

Iron and manganese are absorbed across the intestinal brush border by the same carrier, divalent metal transporter 1 (DMT1), and compete for it_[3]. Expression of DMT1 rises when iron stores fall, so iron deficiency increases manganese uptake rather than reducing it_[4]. This is observable in people: children with iron deficiency anaemia carry raised whole-blood manganese concentrations_[8]. Whether the same competition limits manganese uptake when iron is high is less established in humans. The clearest documented effect of iron sufficiency runs at the cellular level instead: restoring intracellular iron protects cells against manganese's toxic effects, and iron depletion makes them worse_[5].

The competition between the two elements is sometimes described as theoretical, or as something that arises only under unusual circumstances. It is neither. It is the principal determinant of how much of either element is absorbed. Nor can manganese resolve an iron deficiency: iron deficiency is a depletion of iron stores, and no quantity of a different element supplies iron atoms.

Manganese as a Treatment

This site's article originally proposed manganese for a wide range of conditions: stabilising blood sugar in diabetic and hypoglycaemic individuals, treating menopausal symptoms and menstrual problems, asthma, carpal tunnel syndrome, deafness, epilepsy, infertility, low libido, and recurrent joint dislocation. None of that was supported by controlled human trials of manganese supplementation, and the article has since been corrected. The evidence behind that correction:

Blood Sugar and Diabetes

The favourable findings are in animals. Manganese supplementation improved glucose tolerance and enhanced insulin secretion in mice fed a high-fat diet_[16]. Human data are observational and inconsistent, and critically they are not one-directional: plasma manganese shows a U-shaped association with type 2 diabetes, with both low and high levels associated with increased risk_[17]. A framework in which more manganese is better for blood sugar is not what the human data describe.

Menopause and “Strong Estrogenic Properties”

This claim inverted a toxicological finding into a therapy, and it was the most consequential error in the article's original text.

Manganese does influence reproductive endocrinology, but the mechanism is central rather than estrogenic: it acts on the hypothalamus to stimulate luteinizing hormone secretion_[18]. That finding comes from rodent work, and it is studied as a hazard — manganese-induced precocious puberty is investigated as an endocrine-disruption endpoint, including its effects on mammary epithelial cell proliferation_[19]. Manganese is not an estrogen and does not act as one.

The population the article targets is also the population in which higher manganese is associated with harm. In NHANES data, blood manganese was negatively associated with bone mineral density in both sexes, with the effect most pronounced in postmenopausal women, where reduced estradiol appears to amplify it_[20]. Recommending manganese as “the most important element” for menopausal symptoms directs it at the group with the clearest signal of skeletal risk.

The related proposal that manipulating manganese can delay or hasten menopause or restart a menstrual cycle has no human evidence whatsoever, and should not be attempted.

The Remaining Indications

Asthma, carpal tunnel syndrome, deafness, epilepsy, infertility, libido and joint dislocation were asserted without supporting trials. Manganese is genuinely a cofactor in numerous enzyme systems, including manganese superoxide dismutase, arginase, and enzymes of bone matrix formation, and severe experimental depletion produces real effects. Cofactor status does not, however, establish that supplementation treats conditions in people who are not deficient.

Iron Status Testing and Ferritin

The article originally stated that ferritin is the most useful of the routine iron measures and that it is “closest to actual intracellular values.” The first half was broadly right; the second was not supportable, and the article has been corrected to describe ferritin's actual limitation instead.

Ferritin is the recommended first-line test for iron deficiency and correlates with iron stores_[21]_[22]. Its principal limitation is that it is an acute-phase reactant, rising with inflammation, infection, malignancy and liver disease, so that a normal or high value does not exclude iron deficiency_[23]_[24]. The accepted response is to interpret ferritin alongside transferrin saturation, and to use soluble transferrin receptor where inflammation confounds_[23]. That is a different correction from the one the article originally proposed: the answer to ferritin's limitations is additional validated serum markers, not an unvalidated intracellular measurement.

The article's original claim that routine blood tests are unreliable and that a proprietary intracellular assessment performs better was not supported, and has been removed. No qualified biomarker of manganese status has been established at all_[10], whole-blood manganese varies widely between individuals_[9], and the measures that come closest for manganese — serum manganese with lymphocyte manganese superoxide dismutase activity, and possibly blood arginase — remain research tools_[11]. The absence of a routine manganese test is a genuine gap in clinical practice. It is not evidence that an alternative method filled it.

Dose: What Has Actually Been Administered

Because manganese doses far above ordinary intake circulate in nutritional writing, the published record of what has actually been administered is summarised here.

The reference values are an Adequate Intake of 2.3 mg/day for adult men and 1.8 mg/day for adult women, and a Tolerable Upper Intake Level of 11 mg/day for adults, set from a no-observed-adverse-effect level for Western diets_[12]. EFSA has since set a safe level of intake of 8 mg/day for adults, including in pregnancy and lactation_[13]. In NHANES III, the median supplemental manganese intake among adults taking supplements was approximately 2.4 mg/day_[12].

The highest oral doses identified in published human trials come from the glucosamine and chondroitin osteoarthritis literature, where manganese ascorbate was included in the test product. One randomised, double-blind, placebo-controlled study used manganese ascorbate 228 mg/day_[14], and a knee osteoarthritis trial used 152 mg twice daily, 304 mg/day_[15]. Manganese ascorbate is roughly 13 % elemental manganese by mass, which places those protocols in the region of 30 to 40 mg of elemental manganese per day, or about three to four times the Tolerable Upper Intake Level. These were legitimate published trials of a commercial product.

That is the ceiling the published record supports, and it is an order of magnitude below 150 mg/day. It is also worth noting for readers that combination joint-health supplements have been a route by which people consumed manganese well above the UL without being aware of it. Anyone taking such a product should check its elemental manganese content.

Trials above the Upper Intake Level are not improper in themselves. The Institute of Medicine's position is explicit: intake above the UL may be appropriate for investigation within well-controlled clinical trials, provided participants give informed consent regarding possible toxicity and appropriate safety monitoring is in place_[12]. What separates such a trial from an uncontrolled clinical impression is not the dose but that structure — a protocol, a control group, verification of the product administered, and a validated measure of the outcome. A dose reported without any of them establishes nothing, at any level.

Editor's Assessment

A real interaction, with the sign reversed

An editorial reading of the original article and the evidence review above

Assesses both preceding sections · 22 August 2026

The iron–manganese pairing is one of the better intuitions in this body of work. Most of the mineral pairings described on this site have no documented mechanism behind them. This one does: the two elements genuinely compete for the same intestinal transporter, and their balance genuinely matters.

What follows are three places where that sound starting point led to conclusions the mechanism does not support. Numbered references point to the reference list for this article.

1 A Real Interaction, Read Backwards

The article originally opened by stating that “the absorption of iron is dependent on manganese,” and that adding manganese was therefore important when iron was being supplemented.

The Biological Reality: Both elements cross the intestinal wall through DMT1 and compete for it_[3]. Iron deficiency upregulates that transporter, so low iron raises manganese absorption_[4].
The Misinterpretation: Competition was read as dependence. The two elements do not assist one another across the intestinal wall; they obstruct one another, and which one wins depends on iron status. Having identified a genuine interaction, the article characterised it as the opposite of what it is.

2 Cofactor Status Mistaken for Therapeutic Range

Manganese is a cofactor for manganese superoxide dismutase, arginase, and enzymes involved in bone matrix formation and carbohydrate metabolism_[10]. The article originally listed conditions in which those systems are implicated and treated each as an indication for supplementation.

The Biological Reality: An enzyme requiring a cofactor is saturated at ordinary intakes. Adding more of the cofactor does not accelerate the enzyme in someone who is replete.
The Misinterpretation: Enzymology was converted into an indication list — diabetes, epilepsy, deafness, infertility, carpal tunnel, joint dislocation — none of it tested in controlled human trials of manganese.

3 A Toxicology Signal Presented as a Therapy

Manganese was described as having “strong estrogenic properties” and as the most important element for treating menopausal symptoms.

The Biological Reality: Manganese acts centrally on the hypothalamus to stimulate luteinizing hormone secretion_[18]. That effect is studied in animals as endocrine disruption — it produces precocious puberty_[19]. Separately, higher blood manganese is associated with lower bone mineral density, most strongly in postmenopausal women_[20].
The Misinterpretation: A hormonal effect was observed and its sign was reversed: a hazard endpoint became a treatment, aimed at the exact group in which the associated harm is most pronounced.

Summary

Three sign errors followed from one sound premise: a competition described as a dependence, a cofactor read as a remedy, and an endocrine hazard read as a benefit. The interaction the article identified is real and clinically meaningful, and the article has since been corrected so its conclusions match the mechanism that makes it real.

The information is provided for educational purposes only and is not intended for self-treatment — full disclaimer

General recommendations for nutritional supplementation: To avoid stomach problems and improve tolerance, supplements should be taken earlier, or in the middle of a larger meal. When taken on an empty stomach or after a meal, there is a greater risk of some tablets causing irritation, or eventually erosion of the esophageal sphincter, resulting in Gastroesophageal Reflux Disease (GERD). It is also advisable not to lie down right after taking pills. When taking a large daily amount of a single nutrient, it is better to split it up into smaller doses to not interfere with the absorption of other nutrients in food, or nutrients supplemented at lower amounts.